Andrew Dudum Sells 128,127 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum sold 128,127 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $58.27, for a total value of $7,465,960.29. Following the completion of the sale, the chief executive officer now owns 97,687 shares in the company, valued at $5,692,221.49. The trade was a 56.74 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Andrew Dudum also recently made the following trade(s):

• On Friday, January 31st, Andrew Dudum sold 100,000 shares of Hims & Hers Health stock. The stock was sold at an average price of $35.22, for a total value of $3,522,000.00.
• On Thursday, January 23rd, Andrew Dudum sold 27,098 shares of Hims & Hers Health stock. The stock was sold at an average price of $30.08, for a total value of $815,107.84.
• On Tuesday, January 21st, Andrew Dudum sold 300 shares of Hims & Hers Health stock. The stock was sold at an average price of $30.00, for a total value of $9,000.00.
• On Thursday, January 16th, Andrew Dudum sold 36,460 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.09, for a total value of $987,701.40.
• On Monday, December 16th, Andrew Dudum sold 78,127 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.62, for a total value of $2,314,121.74.
• On Monday, December 2nd, Andrew Dudum sold 33,513 shares of Hims & Hers Health stock. The stock was sold at an average price of $33.38, for a total value of $1,118,663.94.

Hims & Hers Health Stock Performance

NYSE:HIMS opened at $49.10 on Friday. The stock has a fifty day moving average price of $35.05 and a 200-day moving average price of $25.70. The company has a market cap of $10.73 billion, a price-to-earnings ratio of 111.58 and a beta of 1.35. Hims & Hers Health, Inc. has a fifty-two week low of $9.25 and a fifty-two week high of $72.98.

Analyst Upgrades and Downgrades

HIMS has been the topic of a number of analyst reports. Morgan Stanley cut Hims & Hers Health from an “overweight” rating to an “equal weight” rating and upped their price objective for the stock from $42.00 to $60.00 in a research note on Tuesday. Canaccord Genuity Group boosted their target price on Hims & Hers Health from $38.00 to $68.00 and gave the stock a “buy” rating in a report on Wednesday. Piper Sandler boosted their target price on Hims & Hers Health from $21.00 to $24.00 and gave the stock a “neutral” rating in a report on Monday, January 6th. Bank of America boosted their target price on Hims & Hers Health from $18.00 to $21.00 and gave the stock an “underperform” rating in a report on Thursday. Finally, TD Cowen reissued a “buy” rating and set a $28.00 target price on shares of Hims & Hers Health in a report on Wednesday, November 20th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $28.53.

Institutional Trading of Hims & Hers Health

A number of institutional investors have recently modified their holdings of HIMS. Farallon Capital Management LLC lifted its position in shares of Hims & Hers Health by 64,338.5% during the 4th quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company’s stock valued at $202,556,000 after acquiring an additional 8,364,000 shares during the period. Arrowstreet Capital Limited Partnership lifted its position in shares of Hims & Hers Health by 192.0% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company’s stock valued at $152,436,000 after acquiring an additional 4,145,305 shares during the period. Vanguard Group Inc. lifted its position in shares of Hims & Hers Health by 11.1% during the 4th quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company’s stock valued at $489,817,000 after acquiring an additional 2,020,722 shares during the period. Yong Rong HK Asset Management Ltd bought a new stake in shares of Hims & Hers Health during the 4th quarter valued at $41,104,000. Finally, Renaissance Technologies LLC lifted its position in shares of Hims & Hers Health by 29.0% during the 4th quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company’s stock valued at $168,079,000 after acquiring an additional 1,562,302 shares during the period. 63.52% of the stock is currently owned by institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.